ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer

Christopher G. England, Anyanee Kamkaew, Hyung Jun Im, Hector F. Valdovinos, Haiyan Sun, Reinier Hernandez, Steve Y. Cho, Edward J. Dunphy, Dong Soo Lee, Todd E. Barnhart, Weibo Cai

Research output: Contribution to journalArticle

Abstract

The role of insulin-like growth factor-1 receptor (IGF-1R) in cancer tumorigenesis was established decades ago, yet there are limited studies evaluating the imaging and therapeutic properties of anti-IGF-1R antibodies. Noninvasive imaging of IGF-1R may allow for optimized patient stratification and monitoring of therapeutic response in patients. Herein, this study reports the development of a Zirconium-89 (89Zr)-labeled anti-IGF-1R antibody (89Zr-Df-1A2G11) for PET imaging of pancreatic cancer. Successful chelation and radiolabeling of the antibody resulted in a highly stable construct that could be used for imaging IGF-1R expressing tumors in vivo. Western blot and flow cytometry studies showed that MIA PaCa-2, BxPC-3, and AsPC-1 pancreatic cancer cell lines expressed high, moderate, and low levels of IGF-1R, respectively. These three pancreatic cancer cell lines were subcutaneously implanted into mice. By employing the PET imaging technique, the tumor accumulation of 89Zr-Df-1A2G11 was found to be dependent on the level of IGF-1R expression. Tumor accumulation of 89Zr-Df-1A2G11 was 8.24 ± 0.51, 5.80 ± 0.54, and 4.30 ± 0.42 percentage of the injected dose (%ID/g) in MIA PaCa-2, BxPC-3, and AsPC-1-derived tumor models at 120 h postinjection, respectively (n = 4). Biodistribution studies and ex vivo immunohistochemistry confirmed these findings. In addition, 89Zr-labeled nonspecific human IgG (89Zr-Df-IgG) displayed minimal uptake in IGF-1R positive MIA PaCa-2 tumor xenografts (3.63 ± 0.95%ID/g at 120 h postinjection; n = 4), demonstrating that 89Zr-Df-1A2G11 accumulation was highly specific. This study provides initial evidence that our 89Zr-labeled IGF-1R-targeted antibody may be employed for imaging a wide range of malignancies. Antibodies may be tracked in vivo for several days to weeks with 89Zr, which may enhance image contrast due to decreased background signal. In addition, the principles outlined in this study can be employed for identifying patients that may benefit from anti-IGF-1R therapy.

Original languageEnglish (US)
Pages (from-to)1958-1966
Number of pages9
JournalMolecular Pharmaceutics
Volume13
Issue number6
DOIs
StatePublished - Jun 6 2016
Externally publishedYes

Fingerprint

Somatomedin Receptors
Pancreatic Neoplasms
Neoplasms
Antibodies
Cell Line
Physiologic Monitoring
Heterografts
Flow Cytometry
Carcinogenesis
Therapeutics
Immunoglobulin G
Western Blotting
Immunohistochemistry

Keywords

  • Insulin-like growth factor-1 receptor (IGF-1R)
  • Molecular imaging
  • Positron emission tomography (PET)
  • Zirconium-89 (Zr)

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Drug Discovery

Cite this

England, C. G., Kamkaew, A., Im, H. J., Valdovinos, H. F., Sun, H., Hernandez, R., ... Cai, W. (2016). ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer. Molecular Pharmaceutics, 13(6), 1958-1966. https://doi.org/10.1021/acs.molpharmaceut.6b00132

ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer. / England, Christopher G.; Kamkaew, Anyanee; Im, Hyung Jun; Valdovinos, Hector F.; Sun, Haiyan; Hernandez, Reinier; Cho, Steve Y.; Dunphy, Edward J.; Lee, Dong Soo; Barnhart, Todd E.; Cai, Weibo.

In: Molecular Pharmaceutics, Vol. 13, No. 6, 06.06.2016, p. 1958-1966.

Research output: Contribution to journalArticle

England, CG, Kamkaew, A, Im, HJ, Valdovinos, HF, Sun, H, Hernandez, R, Cho, SY, Dunphy, EJ, Lee, DS, Barnhart, TE & Cai, W 2016, 'ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer', Molecular Pharmaceutics, vol. 13, no. 6, pp. 1958-1966. https://doi.org/10.1021/acs.molpharmaceut.6b00132
England, Christopher G. ; Kamkaew, Anyanee ; Im, Hyung Jun ; Valdovinos, Hector F. ; Sun, Haiyan ; Hernandez, Reinier ; Cho, Steve Y. ; Dunphy, Edward J. ; Lee, Dong Soo ; Barnhart, Todd E. ; Cai, Weibo. / ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer. In: Molecular Pharmaceutics. 2016 ; Vol. 13, No. 6. pp. 1958-1966.
@article{e87d5e842ff54321b7c102293c53a0bc,
title = "ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer",
abstract = "The role of insulin-like growth factor-1 receptor (IGF-1R) in cancer tumorigenesis was established decades ago, yet there are limited studies evaluating the imaging and therapeutic properties of anti-IGF-1R antibodies. Noninvasive imaging of IGF-1R may allow for optimized patient stratification and monitoring of therapeutic response in patients. Herein, this study reports the development of a Zirconium-89 (89Zr)-labeled anti-IGF-1R antibody (89Zr-Df-1A2G11) for PET imaging of pancreatic cancer. Successful chelation and radiolabeling of the antibody resulted in a highly stable construct that could be used for imaging IGF-1R expressing tumors in vivo. Western blot and flow cytometry studies showed that MIA PaCa-2, BxPC-3, and AsPC-1 pancreatic cancer cell lines expressed high, moderate, and low levels of IGF-1R, respectively. These three pancreatic cancer cell lines were subcutaneously implanted into mice. By employing the PET imaging technique, the tumor accumulation of 89Zr-Df-1A2G11 was found to be dependent on the level of IGF-1R expression. Tumor accumulation of 89Zr-Df-1A2G11 was 8.24 ± 0.51, 5.80 ± 0.54, and 4.30 ± 0.42 percentage of the injected dose ({\%}ID/g) in MIA PaCa-2, BxPC-3, and AsPC-1-derived tumor models at 120 h postinjection, respectively (n = 4). Biodistribution studies and ex vivo immunohistochemistry confirmed these findings. In addition, 89Zr-labeled nonspecific human IgG (89Zr-Df-IgG) displayed minimal uptake in IGF-1R positive MIA PaCa-2 tumor xenografts (3.63 ± 0.95{\%}ID/g at 120 h postinjection; n = 4), demonstrating that 89Zr-Df-1A2G11 accumulation was highly specific. This study provides initial evidence that our 89Zr-labeled IGF-1R-targeted antibody may be employed for imaging a wide range of malignancies. Antibodies may be tracked in vivo for several days to weeks with 89Zr, which may enhance image contrast due to decreased background signal. In addition, the principles outlined in this study can be employed for identifying patients that may benefit from anti-IGF-1R therapy.",
keywords = "Insulin-like growth factor-1 receptor (IGF-1R), Molecular imaging, Positron emission tomography (PET), Zirconium-89 (Zr)",
author = "England, {Christopher G.} and Anyanee Kamkaew and Im, {Hyung Jun} and Valdovinos, {Hector F.} and Haiyan Sun and Reinier Hernandez and Cho, {Steve Y.} and Dunphy, {Edward J.} and Lee, {Dong Soo} and Barnhart, {Todd E.} and Weibo Cai",
year = "2016",
month = "6",
day = "6",
doi = "10.1021/acs.molpharmaceut.6b00132",
language = "English (US)",
volume = "13",
pages = "1958--1966",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer

AU - England, Christopher G.

AU - Kamkaew, Anyanee

AU - Im, Hyung Jun

AU - Valdovinos, Hector F.

AU - Sun, Haiyan

AU - Hernandez, Reinier

AU - Cho, Steve Y.

AU - Dunphy, Edward J.

AU - Lee, Dong Soo

AU - Barnhart, Todd E.

AU - Cai, Weibo

PY - 2016/6/6

Y1 - 2016/6/6

N2 - The role of insulin-like growth factor-1 receptor (IGF-1R) in cancer tumorigenesis was established decades ago, yet there are limited studies evaluating the imaging and therapeutic properties of anti-IGF-1R antibodies. Noninvasive imaging of IGF-1R may allow for optimized patient stratification and monitoring of therapeutic response in patients. Herein, this study reports the development of a Zirconium-89 (89Zr)-labeled anti-IGF-1R antibody (89Zr-Df-1A2G11) for PET imaging of pancreatic cancer. Successful chelation and radiolabeling of the antibody resulted in a highly stable construct that could be used for imaging IGF-1R expressing tumors in vivo. Western blot and flow cytometry studies showed that MIA PaCa-2, BxPC-3, and AsPC-1 pancreatic cancer cell lines expressed high, moderate, and low levels of IGF-1R, respectively. These three pancreatic cancer cell lines were subcutaneously implanted into mice. By employing the PET imaging technique, the tumor accumulation of 89Zr-Df-1A2G11 was found to be dependent on the level of IGF-1R expression. Tumor accumulation of 89Zr-Df-1A2G11 was 8.24 ± 0.51, 5.80 ± 0.54, and 4.30 ± 0.42 percentage of the injected dose (%ID/g) in MIA PaCa-2, BxPC-3, and AsPC-1-derived tumor models at 120 h postinjection, respectively (n = 4). Biodistribution studies and ex vivo immunohistochemistry confirmed these findings. In addition, 89Zr-labeled nonspecific human IgG (89Zr-Df-IgG) displayed minimal uptake in IGF-1R positive MIA PaCa-2 tumor xenografts (3.63 ± 0.95%ID/g at 120 h postinjection; n = 4), demonstrating that 89Zr-Df-1A2G11 accumulation was highly specific. This study provides initial evidence that our 89Zr-labeled IGF-1R-targeted antibody may be employed for imaging a wide range of malignancies. Antibodies may be tracked in vivo for several days to weeks with 89Zr, which may enhance image contrast due to decreased background signal. In addition, the principles outlined in this study can be employed for identifying patients that may benefit from anti-IGF-1R therapy.

AB - The role of insulin-like growth factor-1 receptor (IGF-1R) in cancer tumorigenesis was established decades ago, yet there are limited studies evaluating the imaging and therapeutic properties of anti-IGF-1R antibodies. Noninvasive imaging of IGF-1R may allow for optimized patient stratification and monitoring of therapeutic response in patients. Herein, this study reports the development of a Zirconium-89 (89Zr)-labeled anti-IGF-1R antibody (89Zr-Df-1A2G11) for PET imaging of pancreatic cancer. Successful chelation and radiolabeling of the antibody resulted in a highly stable construct that could be used for imaging IGF-1R expressing tumors in vivo. Western blot and flow cytometry studies showed that MIA PaCa-2, BxPC-3, and AsPC-1 pancreatic cancer cell lines expressed high, moderate, and low levels of IGF-1R, respectively. These three pancreatic cancer cell lines were subcutaneously implanted into mice. By employing the PET imaging technique, the tumor accumulation of 89Zr-Df-1A2G11 was found to be dependent on the level of IGF-1R expression. Tumor accumulation of 89Zr-Df-1A2G11 was 8.24 ± 0.51, 5.80 ± 0.54, and 4.30 ± 0.42 percentage of the injected dose (%ID/g) in MIA PaCa-2, BxPC-3, and AsPC-1-derived tumor models at 120 h postinjection, respectively (n = 4). Biodistribution studies and ex vivo immunohistochemistry confirmed these findings. In addition, 89Zr-labeled nonspecific human IgG (89Zr-Df-IgG) displayed minimal uptake in IGF-1R positive MIA PaCa-2 tumor xenografts (3.63 ± 0.95%ID/g at 120 h postinjection; n = 4), demonstrating that 89Zr-Df-1A2G11 accumulation was highly specific. This study provides initial evidence that our 89Zr-labeled IGF-1R-targeted antibody may be employed for imaging a wide range of malignancies. Antibodies may be tracked in vivo for several days to weeks with 89Zr, which may enhance image contrast due to decreased background signal. In addition, the principles outlined in this study can be employed for identifying patients that may benefit from anti-IGF-1R therapy.

KW - Insulin-like growth factor-1 receptor (IGF-1R)

KW - Molecular imaging

KW - Positron emission tomography (PET)

KW - Zirconium-89 (Zr)

UR - http://www.scopus.com/inward/record.url?scp=84973661438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973661438&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.6b00132

DO - 10.1021/acs.molpharmaceut.6b00132

M3 - Article

C2 - 27054683

AN - SCOPUS:84973661438

VL - 13

SP - 1958

EP - 1966

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 6

ER -